Sarepta Therapeutics, Inc. (SRPT)
OvervaluedFundamental
48
Price
$17.73
Market Cap
$1.96B
Part 1 · What the company is worth
Overview
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$1.47B
Trailing 12 months (through 6/30/2026)
Net Income
$-137M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$-307M
Total Equity
$1.14B
Total Liabilities
$2.21B
Current Ratio
4.42
Interest Coverage
18.35
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$14.74
Current Price
$17.73
Margin of Safety
-20.3%
Fair Value Range
$9.58 - $19.90
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
-62.5%
P/B Ratio
1.23
P/FCF
22.88
Gross Margin
98.6%
ROIC
-24.5%
Profitability Radar
Value Creation (Economic Moat)
ROIC
-24.5%
WACC
6.3%
ROIC − WACC
-30.8 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (10)
- Gross margin 98.6%
- P/FCF 22.88
- P/B ratio 1.23
- Debt/equity ratio
- Positive free cash flow
- Current ratio
- Interest coverage
- Low reliance on intangibles
- Revenue growth 5Y 32.4%
- Share dilution -0.5%
Failed (11)
- EPS shows upward trend
- Price CAGR -3.63%
- ROIC -24.5%
- Operating margin -37.5%
- CapEx intensity
- Return on tangible assets
- DCF valuation (Overvalued)
- ROE -10.0%
- Earnings surprise, average -12.2%
- Net margin trend -9.3% vs -2.6%
- Piotroski F-Score 3/9
Unavailable (5)
- Dividend payout –
- Debt/EBITDA
- Price below Graham Number
- PEG ratio (needs P/E > 0 and growth > 0)
- Earnings quality (operating cash flow / net income)
Piotroski F-Score
Serious financial concerns
Earnings Quality
Low quality: investigate accounting
Share Dilution
Buying back shares. Shareholder friendly
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Ian Michael Estepan | President & COO | 49 |
| Mr. Ryan H. Wong | Executive VP & CFO | 46 |
| Ms. Cristin L. Rothfuss J.D. | Executive VP, General Counsel & Company Secretary | 57 |
| Mr. Douglas S. Ingram Esq., J.D. | Advisor | 62 |
| Dr. Louise R. Rodino-Klapac Ph.D. | President of Research & Development and Technical Operations | 47 |
| Dr. Michael E. Severino M.D. | CEO & Director | 59 |
| Rachael Potter Ph.D. | Chief Scientific Officer | - |
| Tamara Thornton | Director of Finance, Treasury & Investor Relations | - |
| Ms. Alison Nasisi | Executive VP & Chief People Officer | - |
| Dr. Diane L. Berry Ph.D. | Executive VP and Chief of Global Policy & Advocacy Officer | - |
Audit Risk
7
Board Risk
2
Compensation Risk
10
Shareholder Rights Risk
3
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-03-02
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-08-05
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-09-23
via SEC EDGAR
Income History
via SEC EDGAR
Part 2 · The price and its context
This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Market Reaction Profile
How much SRPT moves, measured on its daily prices.
More volatile than 86% of the tracked stocks (90-day volatility).
- Volatility 30d
- 57.6%
- Volatility 90d
- 61.6%
- Beta vs S&P 500 (1y)
- 2.05Correlation 0.33
- Max drawdown (12m)
- -39.2%
- ATR (14d, % of price)
- 5.70%
Earnings reactions
How SRPT moved around its past quarterly results.
Next earnings release
Nov 5, 2026 · In 12 days · Time not known
EPS estimate: 0.36Revenue estimate: $350M
What usually happens
- Over the last 12 releases the stock moved a median of 6.7% the next day, up or down.
- Next-day moves: up 4, down 8 (out of 12).
Release history
| Date | When | EPS est. | EPS actual | Surprise | Gap | 1 day | 5 days |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | After the close | 0.26 | -0.05 | -119.0% | +4.6% | +5.3% | +15.4% |
| May 6, 2026 | After the close | 1.01 | 2.88 | +184.7% | -3.3% | -9.7% | -18.2% |
| Feb 25, 2026 | After the close | -1.26 | -3.93 | -213.0% | -6.2% | -8.0% | -15.2% |
| Nov 3, 2025 | After the close | -0.83 | -0.01 | +98.8% | -37.7% | -33.7% | -29.4% |
| Jul 16, 2025 | After the close | n/a | n/a | n/a | +22.6% | +19.5% | -27.5% |
| Feb 26, 2025 | After the close | n/a | n/a | n/a | -5.5% | -3.6% | +0.8% |
| Jan 8, 2024 | During the session | n/a | n/a | n/a | -0.2% | +5.4% | +20.0% |
| Jan 9, 2023 | During the session | n/a | n/a | n/a | +0.6% | -3.9% | +3.6% |
| Jan 10, 2022 | During the session | n/a | n/a | n/a | -1.7% | -10.9% | -16.8% |
| Oct 15, 2021 | After the close | n/a | n/a | n/a | -0.1% | -3.5% | -4.7% |
| Jan 11, 2021 | During the session | n/a | n/a | n/a | +6.0% | +9.1% | +9.8% |
| Jan 13, 2020 | Before the open | n/a | n/a | n/a | +0.8% | -3.4% | -0.9% |
Release dates from SEC 8-K filings.
Updated 10/24/2026
Historical statistics for educational purposes only. They are not forecasts and not investment advice.
Price reaction to the news
Latest news on SRPT and what the price did next.
- 3/19/2026NegativeSarepta To Request FDA For Traditional Approvals For Duchenne Drugs
Published while the US market was open: the move of that day cannot be split into before and after the news, so no figure is shown.
Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.
Latest News
Recent headlines for SRPT.
- 3/19/2026NEGATIVESarepta To Request FDA For Traditional Approvals For Duchenne Drugs
Sarepta Therapeutics Inc. (SRPT) shares experienced a decline following an update from the U.S. Food and Drug Administration (FDA) and mixed clinical trial results for its Duchenne muscular dystrophy drugs. While the company intends to seek traditional approvals, the market is currently weighing the potential for regulatory success against the less-than-convincing trial data. This uncertainty introduces significant risk for investors, as the path to full approval appears more challenging than initially anticipated, potentially impacting future revenue streams and market valuation.
- 2/25/2026NEUTRALSarepta (SRPT) Q4 2025 Earnings Call Transcript
The market awaits crucial details regarding Sarepta Therapeutics' (SRPT) Q4 2025 earnings call transcript. While the event was scheduled, specific information on financial results, future projections, and updates on key products has not yet been made public. Investors will closely monitor the release of this data to assess the company's performance during the period and its growth prospects, particularly concerning advancements in neuromuscular disease treatments. The immediate lack of details maintains a climate of uncertainty, with the stock potentially reacting significantly once the information becomes available and is analyzed by market participants.